Sector News

Alexion to create 200 jobs in Dublin expansion

May 12, 2015
Life sciences
Biopharma group Alexion has announced plans for a major expansion of its Irish business.
 
Alexion, which is still building the first page of its planned Dublin base, said it will invest a further € 450 million to extend the facility over the next four years.
 
The expansion will see the US-based specialist in rare and ultra rare diseases construct its first biological manufacturing facility outside the US.
 
The company makes Soliris, one of the world’s most expensive drugs, which is used to treat two rare blood conditions.
 
The drug, which costs in the region of € 430,000 per patient per year, received approval for use in Ireland earlier this year after a protracted negotiation.
 
Alexion expects to create 200 jobs with the investment, nearly doubling the numbers employed in Ireland by the company since its arrival here in 2013.
 
Alexion’s Irish executive VP for global operations Julie O’Neill said the project “further underscores our commitment to Ireland and is enabled by our ability to recruit highly competent and professional personnel”.
 
Tanaiste Joan Burton welcomed the announcement and said the company brought the “miracle of hope to parents of children who have life limiting and life threatening conditions”.
 
Also speaking at the announcement, Minister for Enterprise Richard Bruton characterised Alexion as a “wonderful company” whose founders “have fantastic passion”.
 
By Dominic Coyle
 
Source: Irish Times

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend